Table 4.
Multivariate analysis for factors associated with bPFS and TTNI by patient
| Characteristic | HR (95% CI) | P value |
|---|---|---|
| bPFS | ||
| ADT | 0.36 (0.19–0.67) | .001 |
| HSPC | 0.35 (0.18–0.69) | .002 |
| Pre-RT PSA | 1.01 (0.99–1.02) | .48 |
| GTV | 1.23 (1.02–1.45) | .04 |
| status | ||
| M1 | 0.86 (0.33–2.25) | .75 |
| Mx | 1.08 (0.68–1.71) | .74 |
| Nodal disease | 1.34 (0.85–2.12) | .21 |
| Treatment when de novo | 0.56 (0.17–1.85) | .34 |
| TTNI | ||
| GTV | 1.20 (0.96–1.49) | .11 |
| ADT | 0.38 (0.18–0.78) | .009 |
| Site | ||
| Node | 1.44 (0.85–2.44) | .17 |
| HSCP | 0.40 (0.19–0.85) | .02 |
| Pre-RT PSA | 1.008 (0.99–1.03) | .33 |
| T1/T2 | 0.69 (0.40–1.18) | .17 |
| M status | ||
| M1 | 0.99 (0.33–2.92) | .98 |
| Mx | 0.85 (0.51–1.41) | .52 |
| PSA-DT | 0.84 (0.63–1.12) | .24 |
| Treatment when de novo | 0.41 (0.10–1.63) | .21 |
Abbreviations: ADT = androgen deprivation therapy; bPFS = biochemical progression-free survival; CI = confidence interval; GTV = gross tumor volume; HR = ha=ard ratio; HSPC = hormone sensitive prostate cancer; OPC = oligometastatic prostate cancer; PSA = prostate specific antigen; PSA-DT = prostate specific antigen; RT = radiation therapy; TTNI = time to next intervention.